Azithromycin shows lower COPD flare-up rates over one year than roflumilast
Multiple treatments are available for chronic obstructive pulmonary disease (COPD), but identifying which regimen best matches an individual patient's needs remains one of the biggest challenges in care. A new study from researchers at UCLA Health compares two treatment options aimed at preventing exacerbations in patients with COPD.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
